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1. Introduction 
Tumors originally develop from normal cells that acquire the ability to grow aberrantly and 
metastasize to distant organs (Hanahan and Weinberg, 2000). These malignant 
transformations are considered to be induced by the accumulation of multiple 
genetic/epigenetic changes (Yamashita et al., 2008b). Although considered monoclonal in 
origin, cancer is composed of heterogeneous cell populations. This heterogeneity is 
traditionally explained by the clonal evolution of cancer cells through a series of stochastic 
genetic events (clonal evolution model) (Fialkow, 1976; Nowell, 1976). In contrast, cancer 
cells and stem cells have similar capabilities with respect to self-renewal, limitless division, 
and the generation of heterogeneous cell populations. Recent evidence suggests that tumor 
cells possess stem cell features (cancer stem cells) to self-renew and give rise to relatively 
differentiated cells through asymmetric division, thereby forming heterogeneous populations 
(cancer stem cell model) (Clarke et al., 2006; Jordan et al., 2006). Accumulating evidence 
supports the notion that cancer stem cells can generate tumors more efficiently in 
immunodeficient mice than non-cancer stem cells in hematological malignancies and in 
various solid tumors (Al-Hajj et al., 2003; Bonnet and Dick, 1997; O'Brien et al., 2007; Ricci-
Vitiani et al., 2007; Singh et al., 2004). 
 Cancer stem cells are considered to be resistant to chemotherapy and radiotherapy, which 
might be associated with the recurrence of the tumor after treatment (Boman and Huang, 
2008; Dean et al., 2005; Diehn et al., 2009; Zou, 2008). These findings have led to the proposal 
of “destemming” cancer stem cells (Hill and Perris, 2007) in order to induce their 
differentiation into non-cancer stem cells or to eradicate cancer stem cells by inhibiting the 
signaling pathways responsible for their self-renewal. Recent studies have supported this 
proposal and suggest the utility of several factors to induce the differentiation of cancer 
stem cells and facilitate tumor eradication; however, it is still debatable whether the simple 
differentiation of cancer stem cells effectively eradicates tumors. Here, we summarize 
current knowledge on the differentiation of cancer stem cells and discuss the utility and 
limitation of differentiation therapy to eliminate cancer. 
2. Cancer stem cell system 
The consensus definition of a cancer stem cell is a cell within a tumor that possesses the 
capacity to self-renew and to generate the heterogeneous lineages of cancer cells that 
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comprise the tumor, as proposed by the AACR workshop in 2006 (Clarke et al., 2006). Thus, 
cancer stem cells can only be defined experimentally and their self-renewal ability is 
generally evaluated by the capacity of serially transplanted cells in immunodeficient mice. A 
cancer stem cell may give rise to one or two daughter cells that have essentially the same 
ability to replicate and generate differentiated non-cancer stem cells (Fig. 1 upper and lower 
left panels). 
 
 
Fig. 1. Symmetric/asymmetric division of a cancer stem cell  
Asymmetric cell division could be defined by the generation of one cancer stem cell and one 
progenitor cell with the loss of self-renewal capacity (Fig. 1 lower right panel). If both 
progenitors derived from a cancer stem cell lose the capacity of self-renewal by the 
induction of differentiation, the cancer stem cell population would be depleted and the 
tumor would subsequently shrink, according to the conventional cancer stem cell model. 
2.1 Signaling pathways responsible for the self-renewal of cancer stem cells 
A growing body of evidence suggests the similarities of normal stem cells and cancer stem 
cells in terms of their self-renewal and differentiation programs. Indeed, the self-renewal 
and differentiation programs in cancer stem cells are considered to be regulated by several 
signaling pathways that are activated in normal stem cells (Lobo et al., 2007). These 
signaling pathways seem to be activated during the process of normal organogenesis as well 
as carcinogenesis in a tissue-dependent manner (Pardal et al., 2003). Therefore, underscoring 
the significance of these signaling pathways on self-renewal and differentiation is critical for 
the development of treatment strategies specifically targeting cancer stem cells.  
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2.1.1 Wnt/β-catenin signaling 
Wnt/β-catenin signaling has been studied primarily in developing embryos and was 
demonstrated to modulate cell proliferation, migration, and differentiation in a cellular 
context-dependent manner (Decaens et al., 2008; Giles et al., 2003; Moon et al., 2004; Ober et 
al., 2006). Wnt signaling is involved in the decision of stem cells to self-renew or 
differentiate during organogenesis, involving, for example, skin, intestine, bone marrow, 
kidney, and liver development (Moon et al., 2004; Thompson and Monga, 2007). Moreover, 
mutations of genes involved in Wnt/β-catenin signaling have been reported in a wide 
variety of human cancers including colorectal cancer, gastric cancer, skin cancer, ovarian 
cancer, liver cancer, and leukemia (Giles et al., 2003; Merle et al., 2005; Takebe et al., 2010; 
Tan et al., 2008; Vermeulen et al., 2010; Woodward et al., 2007; Zhao et al., 2007).  
Wnt signaling is mediated through a core set of proteins to activate the transcriptional 
programs responsible for cell proliferation and development (Fig. 2). In the absence of Wnt 
proteins, β-catenin is phosphorylated and degraded by the Axin-APC-GSK3β complex. 
Once Wnt proteins bind to their receptor, Frizzled, the degradation complex is inactivated to 
stabilize β-catenin, which leads to its accumulation in the nucleus and interaction with T-cell 
factor (TCF) to activate the transcription of target genes (Moon et al., 2004).  
 
 
Fig. 2. Wnt/β-catenin signaling. APC, adenomatous polyposis coli; β-cat, β-catenin; DSH, 
Dishevelled; Frz, Frizzled; GSK3, glycogen synthase kinase 3; TCF, T-cell factor 
Recent studies have demonstrated that Wnt/β-catenin signaling also plays a role in the 
maintenance of cancer stem cells, including colorectal cancer (Vermeulen et al., 2010), breast 
cancer (Li et al., 2003; Woodward et al., 2007), and liver cancer (Yang et al., 2008). We have 
recently demonstrated that Wnt/β-catenin signaling augments self-renewal and inhibits the 
differentiation of liver cancer stem cells by the expression of the stem cell marker EpCAM, 
which results in the enrichment of the tumor-initiating cell population (Yamashita et al., 
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2008a; Yamashita et al., 2009). We have further demonstrated that small molecules, which 
specifically inhibit the transcriptional activity of the TCF/β-catenin complex, can suppress 
the cell proliferation of EpCAM-positive liver cancer cell lines, suggesting the utility of these 
compounds for the eradication of cancers via the inactivation of Wnt/β-catenin signaling 
(Yamashita et al., 2007). 
2.1.2 Hedgehog signaling 
The Hedgehog signaling pathway was initially identified as a regulator of segmental 
patterning in Drosophila (Nusslein-Volhard and Wieschaus, 1980). Hedgehog signaling is 
activated in developing embryos, especially in the skeleton and neural tube, and regulates 
the cell proliferation, migration, and differentiation of stem cells (Varjosalo and Taipale, 
2008). Several types of cancers are reported to have an activated hedgehog signaling 
pathway, including glioma (Clement et al., 2007), prostate cancer (Sanchez et al., 2005), 
breast cancer (Liu et al., 2006), pancreatic cancer (Li et al., 2007), and hematological 
malignancies (Zhao et al., 2009).  
Hedgehog signaling is regulated by several proteins, including ligands (Sonic Hedgehog, 
Desert Hedgehog, and Indian Hedgehog), the Patched (Ptch) receptor, the Smoothened 
(Smo) transmembrane protein, and the zinc finger transcription factor Gli (Merchant and 
Matsui, 2010) (Fig. 3). In the absence of ligands, Ptch represses the activity of Smo and the 
Gli-mediated transcriptional program is constitutively suppressed (Gli- suppressed). Once 
ligands bind to Ptch, the repression of Smo is released and the Gli-mediated transcriptional 
program is activated (Gli-activated).  
 
 
Fig. 3. Hedgehog signaling. Gli-C, Gli complex; Gli-A, Gli-activated; Hh, Hedgehog; Ptch, 
Patched; Smo, Smoothened 
Accumulating evidence suggests that Hedgehog signaling regulates the self-renewal of 
cancer stem cells in several types of cancer, including glioblastoma and leukemia (Clement 
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et al., 2007; Zhao et al., 2009). Accordingly, Hedgehog signaling inhibitors have been 
clinically tested and might be beneficial for patients with advanced medulloblastoma or 
basal cell carcinoma, although Smo mutations in cancer cells confer resistance against such 
inhibitors (Rudin et al., 2009; Von Hoff et al., 2009; Yauch et al., 2009). 
2.1.3 Notch signaling 
Notch signaling has a pivotal role in regulating cell-to-cell communication during 
embryogenesis (Artavanis-Tsakonas et al., 1999), and is known to regulate stem cell fate in 
various organs (Androutsellis-Theotokis et al., 2006; Fre et al., 2005). Mammalian Notch 
ligands consist of the two structurally distinct families Delta-like ligands (DLLs) and Jagged 
ligands (JAGs), and these ligands are bound to the cell membrane (Fig. 4). The activation of 
Notch signaling is initiated by the binding of these membrane-bound ligands to Notch 
receptors, which results in the release of the Notch intracellular domain into the cytoplasm 
and nucleus by the γ-secretase complex to activate the Notch-specific transcriptional program. 
 
 
Fig. 4. Notch signaling. DLL, Delta-like ligand; JAG, Jagged; NICD, Notch intracellular 
domain 
Notch signaling has been implicated in various types of cancers, including solid tumors and 
leukemia (Pannuti et al., 2010). A growing number of recent studies has demonstrated that 
the activation of the Notch signaling pathway can drive tumor growth via the expansion of 
the cancer stem cell population (Korkaya and Wicha, 2009; Peacock and Watkins, 2008; 
Wilson and Radtke, 2006). Indeed, the Notch signaling pathway has been demonstrated to 
be active in cancer stem cells and to play a critical role in the self-renewal of cancer stem 
cells (Fan and Eberhart, 2008; Fan et al., 2010; Wang et al., 2009). Thus, Notch signaling is 
considered to be a good target for pharmacological inhibition to eradicate cancer stem cells, 
and the effect of Notch inhibitors against Notch, including γ-secretase inhibitors or 
monoclonal antibodies, have been extensively evaluated (Pannuti et al., 2010). 
2.2 Signaling pathways responsible for cancer stem cell differentiation 
Although self-renewal pathways are considered to be critical targets for the eradication of 
cancer stem cells, it is still debatable if differentiation pathways are equally effective for their 
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eradication. Several recent studies have provided evidence of the utility and limitation of 
the cancer stem cell differentiation strategy by modulating the signaling pathways 
responsible for the differentiation of normal stem/progenitor cells. 
2.2.1 Bone morphogenic protein signaling 
Bone morphogenic protein (BMP) signaling is known to be activated during embryogenesis 
and to play a pivotal role in the differentiation of neural and intestinal stem cells (Varga and 
Wrana, 2005). BMPs belong to a subgroup of the transforming growth factor-β superfamily 
and activate signaling through the BMP-receptor (BMPR)-mediated phosphorylation of 
Smad proteins. Interestingly, recent studies have suggested the utility of BMPs to induce the 
differentiation of brain cancer stem cells and facilitate brain tumor eradication (Lee et al., 
2008; Piccirillo et al., 2006). More recently, colorectal cancer stem cells have been shown to 
lack the expression of BMP4, and the administration of BMP4 enhanced the terminal 
differentiation, apoptosis, and chemosensitization of colorectal cancer stem cells (Lombardo 
et al., 2011). Interestingly, the effects of BMP4 on the differentiation of colorectal cancer stem 
cells appeared to be independent of the phosphorylation status of Smad, suggesting the 
importance of non-canonical signaling pathways activated by BMP4 for the differentiation 
of these cells. 
2.2.2 Oncostatin M signaling 
Oncostatin M (OSM) is a pleiotropic cytokine that belongs to the IL-6 family, which includes 
IL-6, IL-11, and leukemia inhibitory factor (LIF). These cytokines share the gp130 receptor 
subunit as a common signal transducer, and activate Janus tyrosine kinases and the signal 
transducer and activator of transcription 3 (STAT3) pathways. However, gp130 forms a 
heterodimer with a unique partner, for example, the IL6 receptor, LIF receptor, or OSM 
receptor (OSMR); thus, each cytokine uniquely induces a certain signaling pathway 
(Heinrich et al., 2003), and OSM is known to exploit distinct signaling in an OSMR-specific 
manner (Kinoshita and Miyajima, 2002). Of note, OSM is known to activate the hepatocytic 
differentiation program in hepatoblasts in an OSMR-specific manner (Kamiya et al., 1999; 
Kinoshita and Miyajima, 2002).  
We recently identified that OSMR is expressed in a subset of liver cancer stem cells 
(Yamashita et al., 2010). Interestingly, OSMR-positive hepatocellular carcinoma (HCC) was 
characterized by the abundant expression of stem cell markers and poorly differentiated 
morphology, suggesting that OSMR is more likely to be expressed in HCC with 
stem/progenitor cell features (Yamashita et al., 2008a). Of note, the OSM-OSMR signaling 
pathway was maintained in these HCCs, and OSM induced hepatocytic differentiation in 
liver cancer stem cells (Fig. 5). 
Unexpectedly, we identified that the hepatocytic differentiation of liver cancer stem cells by 
OSM resulted in enhanced cell proliferation in vitro and modest anti-tumor activity in vivo 
when administered alone. However, we have further demonstrated that OSM-mediated 
hepatocytic differentiation of liver cancer stem cells effectively suppresses HCC growth 
when combined with conventional chemotherapy. It is possible that OSM may boost the 
anti-tumor activity of 5-FU by “exhausting dormant cancer stem cells” through hepatocytic 
differentiation and active cell division (Fig. 6). A similar chemosensitization effect was 
observed in colorectal cancer stem cells differentiated by BMP4 administration (Lombardo 
et al., 2011). 
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Fig. 5. Signaling pathways responsible for the self-renewal and differentiation of liver cancer 
stem cells. CSC, cancer stem cell; OSM, oncostatin M 
 
 
Fig. 6. Effect of oncostatin M (OSM) on exhausting dormant liver cancer stem cells 
3. Limitation of cancer stem cell differentiation 
As described above, some of the signaling pathways for the differentiation of normal stem 
cells may be maintained in cancer stem cells. To induce the differentiation of cancer stem 
cells by specific ligands, the expression of the corresponding receptors bound to ligands is 
clearly required, suggesting the importance of clarifying the mechanisms for receptor 
expression regulation. Interestingly, BMPRs and OSMR were detected in colorectal and liver 
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cancer stem cells, respectively, suggesting the possibility of ligand-induced differentiation 
therapy in the clinic. However, the expression of these receptors might be transcriptionally 
suppressed in a subset of cancers through methylation of their promoter regions (Deng et 
al., 2009; Kim et al., 2009; Lee et al., 2008). Indeed, a recent study suggested that BMP-
mediated brain cancer stem cell differentiation failed in a subset of brain tumors in which 
BMP receptor promoters were methylated and silenced (Lee et al., 2008). Therefore, cancer 
stem cells may acquire resistance against differentiation therapy by additional epigenetic 
changes during the differentiation treatment. 
It has been postulated that both normal stem cells and cancer stem cells are dormant and 
show slow cell cycles. Consistently, cancer stem cells are considered to be more resistant to 
conventional cytotoxic chemotherapeutic agents than non-cancer stem cells, possibly due to 
slow cell cycles as well as the increased expression of ATP-binding cassette (ABC) 
transporters, robust DNA damage responses, and activated anti-apoptotic signaling (Bao et 
al., 2006; Dean et al., 2005; Viale et al., 2009). Therefore, the induction of differentiation 
programs in cancer stem cells may result in cell proliferation of the tumor. Indeed, we 
recently demonstrated that differentiation of liver cancer stem cells by OSM increased cell 
proliferation, at least in vitro (Yamashita et al., 2010). Our data clearly suggested the 
necessity of conventional chemotherapy in addition to differentiation therapy to eradicate 
non-cancer stem cells originating from cancer stem cells. Furthermore, although the 
combination of OSM and conventional chemotherapy effectively inhibited tumor growth in 
our model, we did not observe tumor shrinkage (Yamashita et al., 2010). If both progenitors 
derived from a cancer stem cell lose their self-renewal capacity by the induction of 
differentiation, the tumor should subsequently shrink following the depletion of cancer 
stem cells. However, it is possible that ligand-based differentiation programs cannot 
completely inhibit the self-renewal programs of target cancer stem cells. Thus, the induction 
of differentiation in cancer stem cells with the eradication of non-cancer stem cells might not 
be sufficient for the eradication of the tumor, which may suggest the importance of 
inhibiting self-renewal as well as stimulating the differentiation of cancer stem cells. 
A recent paper suggested that leukemia-initiating cells are composed of genetically diverse, 
functionally distinct populations (Notta et al., 2011), suggesting the clonal evolution of 
leukemia-initiating cells. Accordingly, cancer stem cells in solid tumors may also have a 
distinct tumorigenic/metastatic capacity as well as chemoresistance with certain 
genetic/epigenetic changes in each subclone as a result of clonal evolution. Thus, the cancer 
stem cell model and the clonal evolution model are not considered to be mutually exclusive. 
Therefore, clonal selection of cancer stem cells resistant to differentiation therapy might 
occur with additional genetic/epigenetic changes during treatment as a result of clonal 
evolution. The effects of differentiation therapy on the clonal evolution or genetic diversity 
of cancer stem cells need to be clarified in the future. 
4. Conclusion  
The recent re-emergence of the cancer stem cell hypothesis has provided novel insights on 
the effect of differentiation programs on cancer stem cells for the potential eradication of 
tumors. Although the activation of several signaling pathways by certain cytokines may be 
effective for the differentiation of cancer stem cells, their utility and limitation for tumor 
eradication should be clarified in future to provide novel therapeutic opportunities for 
cancer patients.   
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